Following a full submission
AWMSG advice |
||
| Status: Recommended with restrictions | ||
Ferric carboxymaltose (Ferinject®) is recommended as an option for use within NHS Wales for the treatment of patients with iron deficiency when oral iron preparations are ineffective or cannot be used. Ferric carboxymaltose (Ferinject®) should be restricted for use in non-haemodialysis patients only. AWMSG is of the opinion that Ferric carboxymaltose (Ferinject®) is not suitable for shared care within NHS Wales for the above indication. |
||
|
||
Medicine details |
||
| Medicine name | ferric carboxymaltose (Ferinject®) | |
| Formulation | 50 mg solution for injection/infusion | |
| Reference number | 785 | |
| Indication | Treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests |
|
| Company | Vifor Pharma UK Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Full | |
| Status | Recommended with restrictions | |
| Advice number | 1011 | |
| NMG meeting date | 09/06/2011 | |
| AWMSG meeting date | 13/07/2011 | |
| Ratification by Welsh Government | 01/09/2011 | |
| Date of issue | 07/09/2011 | |